Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is an in vivo genome editing company developing curative genetic medicines for patients with rare and genetic diseases. The company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Metagenomi Therapeutics, Inc. does
In the company’s own words
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is an in vivo genome editing company developing curative genetic medicines for patients with rare and genetic diseases. The company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop novel gene editing tools capable of correcting genetic mutations throughout the human genome. The company's website is located at https://ir.metagenomi.co/.
Metagenomi has generated over 20,000 signature gene editing systems from its proprietary metagenomics database. The company's core technology platform encompasses programmable nucleases including ultra-small SMART nucleases designed for adeno-associated virus packaging, novel base editors capable of simultaneous multiplexed editing, and RNA and DNA-mediated integration systems for large gene insertion and correction. The company leverages machine learning and artificial intelligence to enhance its genome editing capabilities and expand targeting precision beyond commonly used CRISPR/Cas9 systems.
The company's lead program, MGX-001, targets hemophilia A through site-specific genome integration designed to provide durable Factor VIII expression from a single administration. Preclinical data in non-human primates demonstrated therapeutically relevant FVIII activity with a favorable safety profile and no detectable off-target editing. The company plans to submit an investigational new drug application in the fourth quarter of 2026 and initiate clinical trials in 2027. MGX-001's large gene integration system is also being evaluated for additional secreted protein deficiencies, including antithrombin III deficiency, where the company demonstrated proof-of-concept in non-human primates.
Through a collaboration with Ionis Pharmaceuticals initiated in November 2022, Metagenomi is advancing programs targeting cardiometabolic diseases including apolipoprotein C-III for hypertriglyceridemia, transthyretin amyloidosis, and refractory hypertension. The company received an $80 million upfront payment from Ionis and is eligible for additional development, regulatory, and sales-based milestone payments.
In late 2025, the company announced a strategic restructuring focused on advancing its wholly-owned hemophilia A program and later-stage preclinical pipeline while reducing workforce and extending cash runway into the fourth quarter of 2027.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1785279
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Metagenomi Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Metagenomi Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Metagenomi Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Metagenomi Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Metagenomi Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”